Bellerophon Therapeutics, Inc. (BLPH) Stock Rating Lowered by Zacks Investment Research

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

Several other equities analysts have also issued reports on the company. ValuEngine raised Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Bellerophon Therapeutics in a research note on Wednesday, September 6th.

Bellerophon Therapeutics (NASDAQ BLPH) opened at 1.05 on Thursday. The stock’s market cap is $37.29 million. The firm has a 50-day moving average price of $1.08 and a 200 day moving average price of $1.20. Bellerophon Therapeutics has a 1-year low of $0.43 and a 1-year high of $1.69.

Bellerophon Therapeutics (NASDAQ:BLPH) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. On average, equities research analysts anticipate that Bellerophon Therapeutics will post ($1.12) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Bellerophon Therapeutics, Inc. (BLPH) Stock Rating Lowered by Zacks Investment Research” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/09/16/bellerophon-therapeutics-inc-blph-stock-rating-lowered-by-zacks-investment-research.html.

A number of hedge funds and other institutional investors have recently modified their holdings of BLPH. Susquehanna International Group LLP purchased a new stake in Bellerophon Therapeutics during the 2nd quarter worth about $1,316,000. Renaissance Technologies LLC increased its holdings in Bellerophon Therapeutics by 99.7% during the 1st quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock worth $711,000 after purchasing an additional 238,300 shares during the period. Vanguard Group Inc. increased its holdings in Bellerophon Therapeutics by 52.6% during the 2nd quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock worth $821,000 after purchasing an additional 211,111 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new stake in Bellerophon Therapeutics during the 1st quarter worth about $125,000. Institutional investors own 45.85% of the company’s stock.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply